Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
To facilitate risk assessment for pancreatic ductal adenocarcinoma (PDAC) in the general population, we developed time-to-event models using longitudinal structured electronic health record (EHR) data to estimate 6–12, 12–24, and 24–36 months PDAC risk.
The model was developed using UK Biobank (UKB), a lar...
Ji-Fan Gao, Mina Stanikic, Eshna Lahr et al.· Cancer Research· 0 citations
Recent studies have identified a high prevalence of low grade pancreatic intraepithelial neoplasia (PanIN) in the pancreata of healthy adults. This study aimed to characterize the transcriptomic landscape of human PanINs at single cell resolution, with the goal of identifying hallmarks of initiation and progressi...
C. Nguyen, Anders W. Ohman, Winston R. Becker et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.